Do analysts rate TELO or QTTB?

Q32 Bio has a consensus target price of $31.00, indicating a potential upside of 179.28%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts plainly believe Q32 Bio is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Q32 Bio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86

Is TELO or QTTB more profitable?

Q32 Bio's return on equity of 50.17% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -102.70% -90.75% Q32 Bio N/A 50.17% 29.49%

Do analysts rate TELO or ABEO?

Abeona Therapeutics has a consensus price target of $19.33, indicating a potential upside of 257.36%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Abeona Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is TELO or ABEO more profitable?

Abeona Therapeutics' return on equity of -41.69% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -102.70% -90.75% Abeona Therapeutics N/A -41.69% -30.36%

Do analysts rate UPB or TELO?

Upstream Bio presently has a consensus target price of $29.67, suggesting a potential upside of 417.74%. Given Upstream Bio's stronger consensus rating and higher probable upside, analysts clearly believe Upstream Bio is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate SABS or TELO?

SAB Biotherapeutics currently has a consensus price target of $12.00, indicating a potential upside of 251.91%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe SAB Biotherapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SAB Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, SABS or TELO?

SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SAB Biotherapeutics N/A N/A $13.27M -$1.30 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.91 N/A

Is SABS or TELO more profitable?

SAB Biotherapeutics' return on equity of -6.74% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics N/A -6.74% -6.06% Telomir Pharmaceuticals N/A -102.70% -90.75%

Do analysts prefer TELO or LYEL?

Lyell Immunopharma has a consensus target price of $40.86, indicating a potential upside of 241.61%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Lyell Immunopharma is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Telomir Pharmaceuticals (TELO) Competitors

$1.17 -0.01 (-0.85%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.19 +0.02 (+1.37%)

As of 09/11/2026 07:57 PM Eastern

Compare

TELO vs. QTTB, ABEO, UPB, SABS, and LYEL

Should you buy Telomir Pharmaceuticals stock or one of its competitors? Telomir Pharmaceuticals's main competitors and comparable companies include Q32 Bio (QTTB), Abeona Therapeutics (ABEO), Upstream Bio (UPB), SAB Biotherapeutics (SABS), and Lyell Immunopharma (LYEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Telomir Pharmaceuticals compare to Q32 Bio?

Telomir Pharmaceuticals (NASDAQ:TELO) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Q32 Bio had 5 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 6 mentions for Q32 Bio and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.87 beat Q32 Bio's score of 1.25 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Very Positive
Q32 Bio	Positive

Q32 Bio has a consensus target price of $31.00, indicating a potential upside of 179.28%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts plainly believe Q32 Bio is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Q32 Bio has higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A
Q32 Bio	$53.74M	6.15	$29.82M	$3.00	3.70

Q32 Bio's return on equity of 50.17% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%
Q32 Bio	N/A	50.17%	29.49%

Telomir Pharmaceuticals has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

31.3% of Q32 Bio shares are held by institutional investors. 16.4% of Telomir Pharmaceuticals shares are held by company insiders. Comparatively, 34.5% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Q32 Bio beats Telomir Pharmaceuticals on 14 of the 15 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Abeona Therapeutics?

Telomir Pharmaceuticals (NASDAQ:TELO) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Telomir Pharmaceuticals has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

80.6% of Abeona Therapeutics shares are held by institutional investors. 16.4% of Telomir Pharmaceuticals shares are held by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Abeona Therapeutics' return on equity of -41.69% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%
Abeona Therapeutics	N/A	-41.69%	-30.36%

Abeona Therapeutics has a consensus price target of $19.33, indicating a potential upside of 257.36%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Abeona Therapeutics has higher revenue and earnings than Telomir Pharmaceuticals. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A
Abeona Therapeutics	$5.82M	53.15	$71.18M	-$1.09	N/A

In the previous week, Abeona Therapeutics had 5 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 6 mentions for Abeona Therapeutics and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.87 beat Abeona Therapeutics' score of 0.57 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Very Positive
Abeona Therapeutics	Positive

Summary

Abeona Therapeutics beats Telomir Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Upstream Bio presently has a consensus target price of $29.67, suggesting a potential upside of 417.74%. Given Upstream Bio's stronger consensus rating and higher probable upside, analysts clearly believe Upstream Bio is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals has lower revenue, but higher earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$3.16M	99.38	-$143.44M	-$2.90	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

In the previous week, Upstream Bio had 3 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Upstream Bio and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.87 beat Upstream Bio's score of 0.49 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Upstream Bio	Neutral
Telomir Pharmaceuticals	Very Positive

Upstream Bio has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

Telomir Pharmaceuticals has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Upstream Bio's return on equity of -48.40% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

Summary

Upstream Bio beats Telomir Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to SAB Biotherapeutics?

SAB Biotherapeutics (NASDAQ:SABS) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

7.8% of SAB Biotherapeutics shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.87 beat SAB Biotherapeutics' score of 0.72 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
SAB Biotherapeutics	Positive
Telomir Pharmaceuticals	Very Positive

SAB Biotherapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	N/A	N/A	$13.27M	-$1.30	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

SAB Biotherapeutics' return on equity of -6.74% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

SAB Biotherapeutics currently has a consensus price target of $12.00, indicating a potential upside of 251.91%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe SAB Biotherapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

SAB Biotherapeutics beats Telomir Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Lyell Immunopharma?

Telomir Pharmaceuticals (NASDAQ:TELO) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Lyell Immunopharma has a consensus target price of $40.86, indicating a potential upside of 241.61%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Lyell Immunopharma is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Telomir Pharmaceuticals has higher earnings, but lower revenue than Lyell Immunopharma. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A
Lyell Immunopharma	$27K	10,854.36	-$274.45M	-$12.83	N/A

Telomir Pharmaceuticals has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Lyell Immunopharma's return on equity of -91.62% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

Telomir Pharmaceuticals has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market.

In the previous week, Lyell Immunopharma had 8 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 9 mentions for Lyell Immunopharma and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.87 beat Lyell Immunopharma's score of 0.47 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Very Positive
Lyell Immunopharma	Neutral

66.1% of Lyell Immunopharma shares are held by institutional investors. 16.4% of Telomir Pharmaceuticals shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Lyell Immunopharma beats Telomir Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Telomir Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TELO vs. The Competition

Export

Metric	Telomir Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$81.16M	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-1.29	14.25	275.24	25.29
Price / Sales	N/A	1,473.06	655.99	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	6.88	15.12	10.33	6.20
Net Income	-$10.41M	-$22.86M	$3.50B	$358.50M
7 Day Performance	0.86%	-4.34%	-3.32%	-2.35%
1 Month Performance	5.41%	-0.02%	-0.41%	-2.77%
1 Year Performance	-13.97%	40.64%	19.21%	7.63%

Telomir Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TELO Telomir Pharmaceuticals	0.4779 of 5 stars	$1.17 -0.8%	N/A	-14.6%	$81.16M	N/A	N/A	1
QTTB Q32 Bio	3.9855 of 5 stars	$11.14 -4.7%	$31.00 +178.3%	+490.4%	$331.63M	$53.74M	3.71	39	Positive News
ABEO Abeona Therapeutics	1.914 of 5 stars	$5.79 -1.0%	$19.33 +233.9%	-19.9%	$331.07M	$5.82M	N/A	90
UPB Upstream Bio	2.7965 of 5 stars	$5.96 -3.7%	$29.67 +397.8%	-68.0%	$326.44M	$3.16M	N/A	38
SABS SAB Biotherapeutics	3.1317 of 5 stars	$3.48 -4.1%	$12.00 +244.8%	+60.8%	$316.63M	N/A	N/A	140	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TELO) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. QTTB, ABEO, UPB, SABS, and LYEL

How does Telomir Pharmaceuticals compare to Q32 Bio?

Summary

How does Telomir Pharmaceuticals compare to Abeona Therapeutics?

Summary

How does Telomir Pharmaceuticals compare to Upstream Bio?

Summary

How does Telomir Pharmaceuticals compare to SAB Biotherapeutics?

Summary

How does Telomir Pharmaceuticals compare to Lyell Immunopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. QTTB, ABEO, UPB, SABS, and LYEL

How does Telomir Pharmaceuticals compare to Q32 Bio?

Does the media favor TELO or QTTB?

Do analysts rate TELO or QTTB?

Which has higher earnings and valuation, TELO or QTTB?

Is TELO or QTTB more profitable?

Which has more volatility and risk, TELO or QTTB?

Do institutionals and insiders believe in TELO or QTTB?

Summary

How does Telomir Pharmaceuticals compare to Abeona Therapeutics?

Which has more risk & volatility, TELO or ABEO?

Do insiders and institutionals believe in TELO or ABEO?

Is TELO or ABEO more profitable?

Do analysts rate TELO or ABEO?

Which has preferable valuation and earnings, TELO or ABEO?

Does the media favor TELO or ABEO?

Summary

How does Telomir Pharmaceuticals compare to Upstream Bio?

Do analysts rate UPB or TELO?

Which has higher valuation & earnings, UPB or TELO?

Does the media favor UPB or TELO?

Which has more volatility & risk, UPB or TELO?

Is UPB or TELO more profitable?

Summary

How does Telomir Pharmaceuticals compare to SAB Biotherapeutics?

Do insiders and institutionals believe in SABS or TELO?

Does the media prefer SABS or TELO?

Which has more volatility and risk, SABS or TELO?

Which has preferable earnings & valuation, SABS or TELO?

Is SABS or TELO more profitable?

Do analysts rate SABS or TELO?

Summary

How does Telomir Pharmaceuticals compare to Lyell Immunopharma?

Do analysts prefer TELO or LYEL?

Which has better earnings & valuation, TELO or LYEL?

Is TELO or LYEL more profitable?

Which has more risk and volatility, TELO or LYEL?

Does the media favor TELO or LYEL?

Do institutionals & insiders believe in TELO or LYEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools